Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Entegris, Inc.

ENTG

NEUTRAL

May 30, 2026

Research Conclusion

At $139, ENTG is fairly valued to mildly rich. Probability-weighted fair value is ~$121 per share; Street consensus target of $158 fully discounts both deleveraging completion and variant content-intensity view. The high-quality moat (specification lock-in from fab qualification cycles) and secular content-intensity tailwind make ENTG a credible long-term hold, but current price embeds significant bull-case credit and provides ~0.7x reward-to-risk asymmetry. Existing holders should hold; new positions warrant patience for an entry below $120. Trim signal above $160; full exit consideration above $180. Thesis status: INTACT — modestly priced for the bull case.

Company Overview & Moat Assessment

Entegris, Inc. (NASDAQ: ENTG) is a leading global supplier of advanced materials and process solutions to the semiconductor industry, headquartered in Billerica, MA, with ~7,000 employees. Following the $6.5B acquisition of CMC Materials in July 2022, the company operates three reportable segments: Materials Solutions & Services (~36% of revenue, CMP slurries and electronic chemicals), Microcontamination Control (~32%, filtration and purification), and Advanced Materials Handling (~32%, FOUPs and wafer carriers). ENTG's products are deeply embedded in customer fab processes at leading-edge nodes, creating switching costs measured in years and tens of millions of dollars. The investment thesis is a leveraged recovery play: deleverage from ~4x net debt/EBITDA to management's ~2x target, harvest the FY2026-2028 semiconductor upcycle, and capture secular content-intensity growth at 2nm/A16/A14 nodes.

▲ Bull Case

  • ◆Content intensity at N2/A16 is structurally underestimated. Backside power delivery (BSPDN) and GAA transistor formation require new slurry chemistries and additional process steps. Content per wafer at leading-edge could step up 30-50% in FY2026-2028. Revenue trajectory reaches $4.7B by FY2027 (vs. $4.1B base), with FY2027 EBITDA reaching $1.5B.
  • ◆Deleveraging finishes by FY2026, unlocking multiple expansion to 22x. FCF generation of $500-600M annually funds $400-500M annual debt paydown; net leverage breaches 2x at end of FY2026 ahead of schedule. Leverage risk premium (currently 2-3x multiple turns) collapses; EV/EBITDA re-rates to 21-22x on full peer-quality terminal value. Bull-case 12-month price target: ~$190 per share (+37% from current).
  • ◆CMC integration delivers ahead of plan; gross margin reaches 48.5% by FY2030. Synergies at top end of $75-100M guided range; mix shift to advanced-node chemistry with 10-20% pricing premium; volume leverage on fixed manufacturing cost base. EBITDA margin reaches 32% and FCF margin reaches ~20% by FY2030, modestly above ENTG's pre-CMC peak of 47.4% gross margin.

▼ Bear Case

  • ◆Semiconductor cycle disappoints; HBM/AI spend moderates faster than consensus. Hyperscaler capex moderates, consumer electronics remain weak through 2027, memory cycle stays uneven. ENTG revenue declines toward $3.2-3.4B in FY2026-2027. Gross margin retreats to 43.5% on volume under-absorption; FCF declines to $350-400M and deleveraging stalls at 3.5-4x. Bear-case price target: $60-80 per share (-43 to -57% from current).
  • ◆US export controls expand to mature-node specialty chemicals. Currently $300-400M of China revenue from 28nm-65nm chemicals is unrestricted. Regulatory 'long tail' BIS rulemaking could remove $200-350M China revenue. Non-China fab buildout offset takes 18-24 months to materialize; near-term revenue gap is real. CMC integration synergies underdeliver simultaneously ($50M vs. $100M target). Goodwill impairment of $500M-$1B becomes credible.
  • ◆Leverage covenant pressure in true tail event (5% probability). -25%+ EBITDA decline pushes net leverage above 4.5x; credit market repricing constrains capital allocation. Potential covenant waiver or distressed equity raise materializes. Goodwill impairment of $1.5B-$2.5B layered on top creates GAAP loss headlines and covenant complications. Severe downside per-share value: $30-45 (-68 to -78%).
Primary Debate on Wall Street

“The Street debate is NOT 'is ENTG a good business?' — settled at 12 Buy / 6 Hold / 1 Sell. The actual debate has three layers: (1) How much leverage discount is already gone? Bulls see ~$25/share multiple-expansion upside as leverage clears 2x; bears counter that multiple has expanded from 15-17x trough to ~22x, leaving limited room without earnings delivery. (2) Is N2/A16 content-intensity variant view real or hype? Bulls (Bernstein, growth funds) argue BSPDN + GAA add 30-50% content per wafer at leading-edge — structural break; bears argue consensus already captures +3-5% node intensity and unprecedented step-up is undemonstrated in production. (3) What happens to China revenue? Bear case projects $200-400M cliff; consensus assumes gradual attrition of -5% annually, consistent with ENTG's actual disclosed trajectory.”

Top Catalysts
  • ◆Quarterly earnings beat + raised margin guidance (Q2/Q3 2026) — Expected impact +5-10%
  • ◆Net leverage <2x announcement ahead of plan (Q3-Q4 2026) — Expected impact +10-15%
  • ◆TSMC reaffirms $35B+ FY2027 capex; N2 mass production confirmed (TSMC Q2/Q3 earnings) — Expected impact +8-12%
  • ◆Share buyback initiation $300-500M annualized (late 2026) — Expected impact +5-10%
  • ◆High-NA EUV adoption at TSMC/Samsung/Intel for <2nm nodes (2026-2028) — Expected impact +$10-15/share over 5 years
  • ◆Intel 18A / IFS production ramp drives Arizona/Ohio qualification (2026-2027) — Expected impact +5-8%
  • ◆China revenue stabilization; no new BIS restrictions (quarterly check) — Expected impact +5-8%, removes overhang
Top Risks
  • ◆Semiconductor cycle disappointment (P=3/5, I=4/5) — Consumables model cushions vs. WFE; advanced node ramp persists as mitigation
  • ◆China export controls expand to mature-node chemicals (P=3/5, I=4/5) — Monitor BIS rulemaking; non-China fab offset over 18-24 months
  • ◆Leverage covenant pressure in downturn (P=2/5, I=5/5) — FCF strength + incurrence covenant structure provide cushion
  • ◆Interest rate sensitivity on variable rate debt (P=3/5, I=3/5) — Partial hedging; deleveraging reduces exposure
  • ◆CMC goodwill impairment ($4B on balance sheet) (P=2/5, I=4/5) — Non-cash; only matters if triggers covenants
  • ◆Technology disruption via dry process substitution (P=2/5, I=3/5) — Slow-moving; R&D investments in alternatives
  • ◆Severe tail risk (correlated combination) (P=1/5, I=5/5) — All risks combine in one downcycle; -70%+ downside; size position accordingly

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/ENTG/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.

Entegris, Inc. (ENTG) — Investment Memo | Margin of Insight